Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth

Immunotherapies aimed at enhancing natural or endogenous antitumor T-cell immunity in patients affected by advanced malignancies are currently being implemented in the clinic with promising results. In order to optimize therapeutic protocols and monitor the effectiveness of such therapies, reliable...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Gibbons, Rachel M., Harrington, Susan M., Krco, Christopher J., Markovic, Svetomir N., Kwon, Eugene D., Dong, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716732/
https://www.ncbi.nlm.nih.gov/pubmed/23894697
http://dx.doi.org/10.4161/onci.23972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716732/
https://www.ncbi.nlm.nih.gov/pubmed/23894697
http://dx.doi.org/10.4161/onci.23972

Ejemplares similares